| Autor: |
Bizot F; Université Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000, Versailles, France., Vulin A; Université Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000, Versailles, France.; SQY Therapeutics, Université de Versailles St-Quentin, Montigny le Bretonneux, France., Goyenvalle A; Université Paris-Saclay, UVSQ, Inserm, END-ICAP, 78000, Versailles, France. aurelie.goyenvalle@uvsq.fr.; LIA BAHN, Centre scientifique de Monaco, Monaco, Monaco. aurelie.goyenvalle@uvsq.fr. |
| Abstrakt: |
Neuromuscular disorders include a wide range of diseases affecting the peripheral nervous system, which are primarily characterized by progressive muscle weakness and wasting. While there were no effective therapies until recently, several therapeutic approaches have advanced to clinical trials in the past few years. Among these, the antisense technology aiming at modifying RNA processing and function has remarkably progressed and a few antisense oligonucleotides (ASOs) have now been approved. Despite these recent clinical successes, several ASOs have also failed and clinical programs have been suspended, in most cases when the route of administration was systemic, highlighting the existing challenges notably with respect to effective ASO delivery. In this review we summarize the recent advances and current status of antisense based-therapies for neuromuscular disorders, using successful as well as unsuccessful examples to highlight the variability of outcomes depending on the target tissue and route of administration. We describe the different ASO-mediated therapeutic approaches, including splice-switching applications, steric-blocking strategies and targeted gene knock-down mediated by ribonuclease H recruitment. In this overview, we discuss the merits and challenges of the current ASO technology, and discuss the future of ASO development. |
Full text from SpringerLink